{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "Cohort of 29 patients with COVID-19: mean age 48.0 (range 23-73), 15 (51.7%) male, 14 (48.3%) female. 96.6% had undergone resection, 69% had radiation therapy, 69% had temozolomide, 34.5% had bevacizumab, and 6.9% had Tumor Treating Fields (i.e., Optune). Obesity was present in 27.6% of patients and prior tobacco use in 20.7%.",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "U07.1",
              "label": "COVID-19",
              "status": "active"
            }
          ],
          "social_history": [
            {
              "category": "smoking",
              "status": "past",
              "description": "prior tobacco use in 20.7%"
            }
          ],
          "medications": [
            {
              "drug": "Temozolomide",
              "indication": "tumor"
            },
            {
              "drug": "Bevacizumab",
              "indication": "tumor"
            }
          ],
          "procedures": [
            {
              "name": "resection",
              "outcome": "unknown"
            },
            {
              "name": "radiation therapy",
              "outcome": "unknown"
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Primary cancer types in the cohort: Astrocytoma (62.1%), Oligodendroglioma (24.1%), Mesiotemporal angiocentric glioma (6.9%). One patient contracted COVID-19 twice. Median delay between glioma diagnosis and COVID-19 diagnosis: 59 months. At COVID-19 diagnosis: 27.6% were taking dexamethasone and 27.6% were undergoing cancer-specific treatment (2 on clinical trials, 2 receiving temozolomide, 2 on bevacizumab, 1 getting radiation therapy, and 1 undergoing resection).",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C71.9",
              "label": "Malignant neoplasm of brain, unspecified",
              "status": "active"
            }
          ],
          "medications": [
            {
              "drug": "C0011585",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "Malignant neoplasm of brain, unspecified"
            },
            {
              "drug": "C0040053",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "Malignant neoplasm of brain, unspecified"
            },
            {
              "drug": "C0005044",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "Malignant neoplasm of brain, unspecified"
            }
          ],
          "procedures": [
            {
              "name": "C0034813",
              "approach": null,
              "date": null,
              "location": null,
              "performed_by": null,
              "outcome": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Vaccination status prior to COVID-19: Pfizer 10 (34.5%), Moderna 7 (24.1%), Janssen 1 (3.4). Number of vaccinations prior to COVID-19: 0 vaccinations 14 (48.3%), 1 vaccination 1 (3.4%), 2 vaccinations 3 (10.3%), 3+ vaccinations 11 (37.9). Presumed COVID-19 variant: Original 11 (37.9%), Epsilon 1 (3.4%), Alpha 2 (6.9%), Omicron 15 (51.7%).",
        "clinical_data": {
          "social_history": [
            {
              "category": "vaccination",
              "status": "past",
              "description": "Pfizer 10 (34.5%), Moderna 7 (24.1%), Janssen 1 (3.4). Number of vaccinations prior to COVID-19: 0 vaccinations 14 (48.3%), 1 vaccination 1 (3.4%), 2 vaccinations 3 (10.3%), 3+ vaccinations 11 (37.9)"
            }
          ],
          "diagnoses": [
            {
              "code": "UMLS:C4723447",
              "label": "COVID-19",
              "status": "suspected",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "COVID-19 symptoms: cough/sore throat/congestion (48.3%), fever (20.7%), shortness of breath/chest pain (20.7%), myalgia/fatigue (20.7%), loss of taste/smell (10.3%), headache (6.9%), and seizures (6.9%); 20.7% were asymptomatic. COVID-19 diagnosis delayed cancer-related care in 5 patients (17.2%). 82.8% did not require hospital admission. 5 patients were admitted, 2 received COVID-19-directed treatment (remdesivir in both cases, dexamethasone in one case).",
        "clinical_data": {
          "HPI": [
            {
              "summary": "COVID-19 symptoms: cough, sore throat, congestion, fever, shortness of breath, chest pain, myalgia, fatigue, loss of taste, loss of smell, headache, and seizures.",
              "associated_symptoms": [
                "C0010200",
                "C0037532",
                "C0009450",
                "C0015967",
                "C0037223",
                "C0008031",
                "C0234175",
                "C0015672",
                "C0271262",
                "C0234176",
                "C0018681",
                "C0036865"
              ]
            }
          ],
          "diagnoses": [
            {
              "code": "UMLS:C4729361",
              "label": "COVID-19",
              "status": "active"
            }
          ],
          "medications": [
            {
              "drug": "UMLS:C5203701",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "UMLS:C4729361"
            },
            {
              "drug": "UMLS:C0011602",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": "UMLS:C4729361"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "Among the 5 admitted patients: 1 had received 3 COVID-19 vaccines, 4 were not vaccinated, 2 were taking dexamethasone, 3 were not receiving dexamethasone, and none were receiving cancer-directed treatment. In the cohort, 55% had a KPS that remained the same or improved after contracting COVID-19, whereas KPS worsened in 20.7%.",
        "clinical_data": {
          "medications": [
            {
              "drug": "dexamethasone",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "social_history": [
            {
              "category": "vaccination",
              "status": "past",
              "description": "received 3 COVID-19 vaccines"
            },
            {
              "category": "vaccination",
              "status": "never",
              "description": "not vaccinated"
            }
          ],
          "functional_status": [
            {
              "domain": "general",
              "description": "KPS remained the same or improved after contracting COVID-19",
              "score": "55",
              "scale": "KPS"
            },
            {
              "domain": "general",
              "description": "KPS worsened after contracting COVID-19",
              "score": "20.7",
              "scale": "KPS"
            }
          ]
        }
      }
    },
    {
      "id": "N6",
      "label": "Step 6",
      "customData": {
        "node_id": "F",
        "node_step_index": 5,
        "content": "By July 13, 2022, 5 patients (17.2%) had died from reasons unrelated to COVID-19 or its complications.",
        "clinical_data": {}
      }
    },
    {
      "id": "N7",
      "label": "Step 7",
      "customData": {
        "node_id": "G",
        "node_step_index": 6,
        "content": "Hospitalization rate was 17.2%. Only 6.9% of patients qualified for and received COVID-19-specific treatment during admission. By the end of analysis; all but 1 patient had eventually become vaccinated. COVID-19 reinfection rate: 1 patient (3.4%).",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "UMLS:C4720989",
              "label": "COVID-19",
              "status": "active"
            }
          ],
          "procedures": [
            {
              "name": "UMLS:C0007424",
              "outcome": "UMLS:C0042046"
            }
          ],
          "social_history": [
            {
              "category": "vaccination",
              "status": "current",
              "description": "COVID-19 vaccination"
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Transition from initial cohort characteristics to primary cancer types, COVID-19 diagnosis timing, and concurrent treatments."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Transition from cancer and COVID-19 diagnosis to vaccination status and presumed COVID-19 variant."
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Transition from vaccination status and COVID-19 variant to COVID-19 symptoms, impact on cancer care, and treatment details."
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Transition from COVID-19 symptoms and treatment to outcomes in admitted patients and changes in KPS."
      }
    },
    {
      "from": "N5",
      "to": "N6",
      "data": {
        "edge_id": "E_to_F",
        "branch_flag": true,
        "content": "Transition from KPS status to mortality unrelated to COVID-19."
      }
    },
    {
      "from": "N6",
      "to": "N7",
      "data": {
        "edge_id": "F_to_G",
        "branch_flag": true,
        "content": "Transition from mortality data to hospitalization rate, COVID-19-specific treatment, vaccination status at the end of analysis, and reinfection rate."
      }
    }
  ]
}